Acquisition of the vaccine specialist, including immunization against hepatitis B, aims to expand the presence of the French pharmaceutical company in the adult immunization market
Sanofi announced it has agreed to buy vaccine specialist Dynavax Technologies in a $2.2 billion all-cash deal, seeking to strengthen the French drugmaker’s immunization portfolio after suffering setbacks in clinical trials.
Under the deal, Sanofi will initiate a $15.50 per share cash tender offer to acquire all of Dynavax, which has a U.S.-approved hepatitis B vaccine and a shingles vaccine candidate in development, the companies said Wednesday.
The deal was unanimously approved by Dynavax’s board, the companies said.
“Dynavax enhances Sanofi’s presence in adult immunization by adding differentiated vaccines that complement Sanofi’s expertise,” said Thomas Triomphe, executive president of vaccines at Sanofi.
For Dynavax, joining Sanofi will help amplify the impact of its vaccines due to the French company’s commercial reach and development capabilities, said Dynavax CEO Ryan Spencer.
Sanofi said it plans to finance the acquisition with existing cash resources and does not expect any impact on its 2025 guidance.
Continues after advertising
Closing of the deal is expected in the first quarter of 2026, subject to conditions, the companies said.
